Wednesday, 17th August 12pm (AEST)
Hear from a selection of CEOs who provide a succinct overview of big things their companies are doing, followed by an interactive Q&A.
This week we are joined by:
- (ASX: ADR) Adherium Limited – a global leader in connected respiratory medical devices, with more than 170,000 sold and 180 patents and designs globally.
- (ASX: EBR) EBR Systems Inc – the world’s only provider of wireless, endocardial (inside the heart) pacing systems in a US$2.5 billion addressable market.
This is a live and interactive online session, and participants are encouraged to ask questions. Spots are limited, so secure yours today.
CEO - Adherium Limited (ASX: ADR)
Adherium provides connected medical devices for respiratory medications for patients, pharmaceutical companies, healthcare providers and contract research organisations. Founded in 2001 and listed on the ASX in 2015, the company’s strategy is focused on the digital health landscape – a US$34 billion market opportunity. Adherium’s Hailie sensor technology and cloud-based data platform provides real-time feedback on patients’ use of inhaled medication, enabling optimal management of difficult-to-treat and severe asthma and Chronic Obstructive Pulmonary Disease (COPD), and reducing healthcare costs. In 2021, Adherium was awarded a supply contract with AstraZeneca for a bespoke version of its Hailie sensor and software solution for its US study.
CEO - EBR Systems Inc (ASX: EBR)
EBR Systems provides safe, cost-effective and reliable therapies using wireless cardiac stimulation for millions of patients suffering from cardiac rhythm diseases. The company’s WiSE technology is the world’s only wireless, endocardial (inside the heart) pacing system in clinical use for stimulating the heart’s left ventricle (LV). The WiSE technology platform provides EBR with an initial addressable market of US$2.5 billion with rapid adoption of leadless devices supporting strong growth. The company’s technology is protected by over 97 issued patents globally and currently has no direct competitors known to be developing leadless LV pacing technology for Cardiac Resynchronisation Therapy (CRT).